New Options for Sleep Apnea When CPAP Fails
A review of sleep apnea treatments beyond CPAP, from mouthpieces and myofunctional therapy to implanted nerve stimulators, supports more personalized care.
Summary
Obstructive sleep apnea (OSA) repeatedly interrupts breathing during sleep, and many people cannot tolerate the standard treatment, a CPAP mask. This review surveys alternatives. Established options include mandibular advancement devices, which are mouthpieces that mechanically widen the airway, and weight loss, which targets a major modifiable risk factor. Newer approaches include daytime tongue stimulation, intraoral negative pressure therapy, nasal expiratory positive airway pressure devices, positional therapy (avoiding sleeping on the back), and orofacial myofunctional therapy, which is exercise training for the mouth and throat muscles. Implantable hypoglossal nerve stimulators, such as Inspire, are described as an effective treatment for moderate-to-severe OSA. The authors conclude that this wider toolkit supports a more personalized approach. This summary is based on the abstract only, so effect sizes, trial quality and head-to-head comparisons are not available here.
Detailed Summary
Obstructive sleep apnea disrupts sleep and oxygen levels night after night, and it is tied to cardiovascular, metabolic and brain health. CPAP is the standard therapy, but many people cannot or will not use it. Finding effective alternatives matters for anyone trying to protect sleep quality and healthspan.
This narrative review in Neurologic Clinics surveys current and emerging OSA treatments, with an emphasis on patients who do not tolerate CPAP. Based on the abstract, it is a review of existing therapies rather than a new trial, and it reports no pooled data.
The abstract describes established options first. Mandibular advancement devices mechanically enlarge the airway. Weight-loss interventions address a major modifiable risk factor. Newer options include daytime tongue stimulation, intraoral negative pressure therapy, nasal expiratory positive airway pressure devices, positional therapy and orofacial myofunctional therapy. Implantable hypoglossal nerve stimulation systems, including Inspire and other FDA-approved devices, are described as effective for moderate-to-severe OSA.
The mechanisms are mostly mechanical or neuromuscular: widening the airway, keeping the tongue from collapsing backward, changing airway pressure, avoiding positions that worsen collapse, or strengthening upper airway muscles. The authors frame the growing list as support for a personalized approach, matching therapy to the patient's anatomy, severity and preferences.
The practical implication is that a CPAP intolerance need not mean untreated apnea. Anyone with suspected or diagnosed OSA can discuss these options with a sleep physician.
Caveats are significant. Only the abstract was available, so there are no details on trial sizes, apnea-hypopnea index reductions, long-term outcomes, adverse effects or comparative effectiveness. The abstract does not report whether any of these treatments improve cardiovascular events, cognition or lifespan, and it does not distinguish the evidence strength of each option. Effectiveness claims for the newer therapies should be checked against the full text and primary trials.
Key Findings
- The review covers OSA treatments for people who cannot tolerate CPAP.
- Mandibular advancement devices work mechanically by enlarging the airway; weight loss targets a major modifiable risk factor.
- Newer options include daytime tongue stimulation, intraoral negative pressure, nasal expiratory pressure devices, positional therapy and myofunctional therapy.
- Implantable hypoglossal nerve stimulators, including Inspire, are described as effective for moderate-to-severe OSA.
- The abstract reports no outcome data on cardiovascular events, cognition or lifespan.
Methodology
This is a narrative review of current and emerging OSA therapies, published in Neurologic Clinics. The abstract does not describe a search strategy, inclusion criteria or evidence grading. No pooled quantitative results are reported in the abstract.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, so effect sizes, evidence quality and safety details are unavailable. The abstract does not compare therapies head to head or report long-term or hard outcomes such as cardiovascular events. As a narrative review, it may reflect selective inclusion of studies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
